| Project Detail |
The aim of the project is to validate the technical and economic feasibility of AXVIRIUM BIOACTIVE TECNOLOGY (ABT) an innovative biomedical device, based on the Adantium® Plus and Axivirium BIOACTIVE® molecules, enable to cut biological risks, improve efficiency and reduce cost of health care biomedical fluids disposal. Medical waste is posing a growing problem worldwide resulting in nearly 7000 tons every day of infectious /hazardous medical waste and 10 billion euro annually in disposal cost across the European health care industry. According to the World Health Organisation (WHO), incorrect and improper management of healthcare biological fluids can have direct impacts on the community, individuals working in health care facilities, and the natural environment. It estimated that at world level accidents caused by not proper biological risks management accounted for 66,000 cases of infection with the hepatitis B virus, 16,000 cases of infection with hepatitis C virus and 200 to 5,000 cases of HIV infection amongst the personnel of health-care facilities. Compared to competitors ABT is the unique solution able to reach 100% degradation of RNases almost in real time and completely sterilize biological fluids. This imply saving operational cost up to 20%, decreasing occupational diseases by 39% and reducing cross- nosocomial infection by 14%. In 2018, the valuation of the global fluid management market was EUR 10 billion and is anticipated to reach EUR 18 billion by 2022, at a positive CAGR of 4.8% in the next three years. The estimated market potential for ABT is about 21 million euro and we estimate to hire 23 high skilled employees. The feasibility study comprises an investigation of market structures, segments and barriers, a customer survey and product validation, the identification of key commercial partners and the development of an IP strategy. |
